Table 1.
Tumor and patient characteristics stratified by different groups.
| Characteristics | Total n = 1306 (%) | HER2-neg n = 1079 (%) | HER2-pos-T n = 227 (%) | P value |
|---|---|---|---|---|
| Age (y/o) | 0.541 | |||
| <35 | 53 (4.1) | 43 (4.0) | 10 (4.4) | |
| 35–50 | 525 (40.2) | 427 (39.6) | 98 (43.2) | |
| >50 | 728 (55.7) | 609 (56.4) | 119 (52.4) | |
| Menstrual status | 0.089 | |||
| Pre/Peri- | 635 (48.6) | 513 (47.5) | 122 (53.7) | |
| Post- | 671 (51.4) | 566 (52.5) | 105 (46.3) | |
| Family history | 0.788 | |||
| No | 1238 (94.8) | 1022 (94.7) | 216 (95.2) | |
| Yes | 68 (5.2) | 57 (5.3) | 11 (4.8) | |
| Breast surgery | 0.015 | |||
| Mastectomy | 944 (72.3) | 765 (70.9) | 179 (78.9) | |
| BCS | 362 (27.7) | 314 (29.1) | 48 (21.1) | |
| Histology type | 0.696 | |||
| IDC | 1216 (93.1) | 1006 (93.2) | 210 (92.5) | |
| Non-IDC | 90 (6.9) | 73 (6.8) | 17 (7.5) | |
| Tumor size | 0.039 | |||
| ≤2.0 cm | 464 (35.6) | 397 (36.9) | 67 (29.6) | |
| >2.0 cm | 839 (64.4) | 680 (63.1) | 159 (70.4) | |
| ALN status | 0.001 | |||
| Negative | 618 (47.3) | 487 (45.1) | 131 (57.7) | |
| Positive | 688 (52.7) | 592 (54.9) | 96 (42.3) | |
| Histological grade | <0.001 | |||
| Ⅰ/Ⅱ | 707 (58.2) | 622 (62.1) | 85 (40.1) | |
| Ⅲ | 507 (41.8) | 380 (37.9) | 127 (59.9) | |
| LVI | 0.171 | |||
| No | 1218 (93.3) | 1011 (93.7) | 207 (91.2) | |
| Yes | 88 (6.7) | 68 (6.3) | 20 (8.8) | |
| ER | <0.001 | |||
| <10% | 59 (4.5) | 35 (3.2) | 24 (10.6) | |
| 10–50% | 240 (18.4) | 178 (16.5) | 62 (27.3) | |
| >50% | 1007 (77.1) | 866 (80.3) | 141 (62.1) | |
| PR | <0.001 | |||
| <20% | 663 (50.8) | 513 (47.5) | 150 (66.1) | |
| ≥20% | 643 (49.2) | 566 (52.5) | 77 (33.9) | |
| Ki-67 | <0.001 | |||
| <14% | 424 (32.5) | 394 (36.5) | 30 (13.2) | |
| ≥14% | 882 (67.5) | 685 (63.5) | 197 (86.8) | |
| Endocrine therapy | 0.739 | |||
| No | 80 (6.1) | 65 (6.0) | 15 (6.6) | |
| Yes | 1226 (93.9) | 1014 (94.0) | 212 (93.4) | |
| Chemotherapy | <0.001 | |||
| A | 150 (11.6) | 149 (13.9) | 1 (0.4) | |
| T | 405 (31.2) | 393 (36.7) | 12 (5.3) | |
| A-T | 632 (48.7) | 448 (41.8) | 184 (81.8) | |
| A + T | 59 (4.5) | 56 (5.2) | 3 (1.3) | |
| Others | 51 (3.9) | 26 (2.4) | 25 (11.1) |
Abbreviations: HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ALN: axillary lymph node; LVI, lymph-vascular invasion; ER, estrogen receptor; PR, progesterone receptor; A: anthracycline; T: taxane; y/o, years old.